FDA Approves Pembrolizumab + Axitinib for Advanced Renal Cell Carcinoma
On April 19, the FDA approved pembrolizumab (Keytruda, Merck & Co. Inc.) plus axitinib (Inlyta, Pfizer Inc.) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
In Person Meeting & NetworkingMay 6, 2026 at 8:00 AM EDT560 King Street, Charleston, SC, USAHyatt Place + Hyatt House Charleston - Historic District, Charleston
In Person Conference & ConventionApril 15, 2026 at 5:00 PM CDTPark Pl Blvd, St. Louis Park, MN, USADoubleTree by Hilton Hotel Minneapolis - Park Place, St. Louis Park
